New Drug for Chronic Myeloid Leukemia Might Stimulate the Market

The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerabilit...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 27; no. 1; pp. 3 - 4
Main Author Müller, Martin C.
Format Journal Article
LanguageEnglish
Published United States 01.01.2021
Online AccessGet full text

Cover

Abstract The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability. See related article by Zhang et al., p. 70
AbstractList The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability. .
The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability.See related article by Zhang et al., p. 70.The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability.See related article by Zhang et al., p. 70.
The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability. See related article by Zhang et al., p. 70
Author Müller, Martin C.
Author_xml – sequence: 1
  givenname: Martin C.
  surname: Müller
  fullname: Müller, Martin C.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33109738$$D View this record in MEDLINE/PubMed
BookMark eNqFkMlOwzAURS1URAf4BJCXbFLs2E4csQGFUWpBYlhbrvvcmmYojiPUvydVCws2rN5bnHule4aoV9UVIHRKyZhSIS8oSWVEOIvHef4SxSRiieQHaECFSCMWJ6LX_T9MHw2b5oMQyinhR6jPGCVZyuQAXT3BF77x7QLb2uN86evKGTzdQFG7OZ5Au4LSaTx1i2XAr8GVbaED4LAEPNV-BeEYHVpdNHCyvyP0fnf7lj9Ek-f7x_x6EhkmkhCBpsAIpzY2IrMWUsMhscZQSazWc8Mt50CJEJbLboGWLJsLMuNE0pk1MmMjdL7rXfv6s4UmqNI1BopCV1C3jYq5EDSNiWQderZH21kJc7X2rtR-o35Wd4DYAcbXTePB_iKUqK1dtTWntuZUZ1fFRG3tdrnLPznjgg6uroLXrvgn_Q2rPn48
CitedBy_id crossref_primary_10_54457_DR_202301002
crossref_primary_10_3389_fonc_2023_1101738
Cites_doi 10.1038/s41375-020-0776-2
10.1038/leu.2014.153
10.1038/leu.2010.169
10.1158/1078-0432.CCR-20-1600
10.1200/JCO.2009.26.3087
ContentType Journal Article
Copyright 2020 American Association for Cancer Research.
Copyright_xml – notice: 2020 American Association for Cancer Research.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1158/1078-0432.CCR-20-3684
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 4
ExternalDocumentID 33109738
10_1158_1078_0432_CCR_20_3684
Genre Comment
Journal Article
GroupedDBID ---
18M
29B
2FS
2WC
34G
39C
53G
5GY
5RE
5VS
6J9
AAFWJ
AAJMC
AAYXX
ABOCM
ACGFO
ACIWK
ACPRK
ACSVP
ADBBV
ADCOW
ADNWM
AENEX
AFHIN
AFOSN
AFRAH
AFUMD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BR6
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FRP
GX1
IH2
KQ8
L7B
LSO
OK1
P0W
P2P
QTD
RCR
RHI
RNS
SJN
TR2
W2D
W8F
WOQ
YKV
NPM
RHF
7X8
ID FETCH-LOGICAL-c356t-ea1e3041f2c59ffe7c4e6fcc180faadc4f44e1055f48557a839d50b4081bfc893
ISSN 1078-0432
1557-3265
IngestDate Fri Jul 11 00:54:55 EDT 2025
Wed Feb 19 02:30:31 EST 2025
Thu Apr 24 23:12:46 EDT 2025
Tue Jul 01 01:30:35 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2020 American Association for Cancer Research.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c356t-ea1e3041f2c59ffe7c4e6fcc180faadc4f44e1055f48557a839d50b4081bfc893
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
OpenAccessLink https://aacrjournals.org/clincancerres/article-pdf/27/1/3/2067117/3.pdf
PMID 33109738
PQID 2455172083
PQPubID 23479
PageCount 2
ParticipantIDs proquest_miscellaneous_2455172083
pubmed_primary_33109738
crossref_primary_10_1158_1078_0432_CCR_20_3684
crossref_citationtrail_10_1158_1078_0432_CCR_20_3684
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-01
2021-Jan-01
20210101
PublicationDateYYYYMMDD 2021-01-01
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2021
References Zhang (2022061101492711500_bib1) 2021; 27
Marin (2022061101492711500_bib2) 2010; 28
Hochhaus (2022061101492711500_bib4) 2020; 34
Hanfstein (2022061101492711500_bib3) 2014; 28
Luo (2022061101492711500_bib5) 2010; 24
32928796 - Clin Cancer Res. 2021 Jan 1;27(1):70-77
32928796 - Clin Cancer Res. 2020 Sep 14
References_xml – volume: 34
  start-page: 966
  year: 2020
  ident: 2022061101492711500_bib4
  article-title: European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/s41375-020-0776-2
– volume: 28
  start-page: 1988
  year: 2014
  ident: 2022061101492711500_bib3
  article-title: Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
  publication-title: Leukemia
  doi: 10.1038/leu.2014.153
– volume: 24
  start-page: 1807
  year: 2010
  ident: 2022061101492711500_bib5
  article-title: HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance
  publication-title: Leukemia
  doi: 10.1038/leu.2010.169
– volume: 27
  start-page: 70
  year: 2021
  ident: 2022061101492711500_bib1
  article-title: Flumatinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase 3, randomized, open-label, multi-center FESTnd study
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-20-1600
– volume: 28
  start-page: 2381
  year: 2010
  ident: 2022061101492711500_bib2
  article-title: Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2009.26.3087
– reference: 32928796 - Clin Cancer Res. 2021 Jan 1;27(1):70-77
– reference: 32928796 - Clin Cancer Res. 2020 Sep 14;:
SSID ssj0014104
Score 2.3525848
Snippet The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 3
Title New Drug for Chronic Myeloid Leukemia Might Stimulate the Market
URI https://www.ncbi.nlm.nih.gov/pubmed/33109738
https://www.proquest.com/docview/2455172083
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdbB2MvpfvOvtBgb8GZLcsfeevmtSsj7mAkkDchyycIa5OSJQ_bX787SXYbyFi3FxMEks39Luef5PvdMfZuPJboJlSnsoE8kmPAv1QqsqhtSpBNDvhKIr1zfZ6fzeSXeTa_7vjp1CWbZmR-7dWV_A-qOIa4kkr2H5DtF8UB_I344hURxuutMKbkxE_rrU-FDGVuh_VPuFgt2uEEtt_hcqGHNe2_kVUuLqlVFziqWTux801mWnUSSUN-sB6GKkD9aXFNn9Q_Vp1y0JcfCGes4dRAJDdODUKgyzC4CN-nYQR7xkJ09Mr9HS_woS7dH4Cz0p0FUN1e9IJRVX2LSKOd-0ZwuwWvz7-q09lkoqYn8-lddk8g06cmFJ_nfZYOZaG6xIDu0YIIC2_zfu9NdunFH_YMjjtMj9hhIP38g0fwIbsDy0fsfh3SGh6zYwSSE5AcgeQBSB6A5B2Q3AHJeyA5Ask9kE_Y7PRkWp1FobVFZNIs30SgE0hjmVhhsrG1UBgJuTUmKWOrdWuklRKod6ml4j2FRhrbZnEjkcA11iDHfMoOlqslPGfcyKKIE7BpCkZqjRvetsx1afLSCFxVDpjsLKJMqPtO7UculNv_ZaUiQyoypEJDKhErMuSAjfppV77wyd8mvO3MrTBE0XcnvYTV9ocSEml5IZDsD9gzj0O_ZEqVaYu0fHGL2S_Zg2tXfsUONustvEZKuGneOKf5DSwZWTc
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+Drug+for+Chronic+Myeloid+Leukemia+Might+Stimulate+the+Market&rft.jtitle=Clinical+cancer+research&rft.au=M%C3%BCller%2C+Martin+C&rft.date=2021-01-01&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=27&rft.issue=1&rft.spage=3&rft_id=info:doi/10.1158%2F1078-0432.CCR-20-3684&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon